GSK shutting down Biopolis neural unit

Other ongoing investments here not affected; UK pharma giant remains committed to R&D in Singapore


IN a move to cut costs, United Kingdom pharma giant GlaxoSmithKline (GSK) will begin a phased closure of its operations at its neural pathways discovery performance unit at Biopolis, following its global review to refocus the global pharmaceuticals business.

While it declined to reveal the number of employees affected by the closure, the drugmaker, which employs 1,700 people here, said it remains committed to research and development (R&D) in Singapore, which is a "a key location for GSK's...

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to